Adriamycin

Breast Adenocarcinoma

Virginia Commonwealth UniversitySmall moleculePhase 3Active

BB

68/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 57/ 100
Competitive Position: 89/ 100

Competitive context

24 Active assets in the Breast Adenocarcinoma cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 3	BB
TRASTUZUMAB Academic and Community Cancer Research United	Phase 3	BB
Letrozole Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	Phase 4	BB
Carboplatin Genmab	Phase 3	BB
Pembrolizumab Genmab	Phase 2	BB

View all 50 →

Same molecule, other indications

Adriamycin is also rated in:

adult acute lymphoblastic leukemiaActive

BBB

Indicative · Phase 4

77 / 100

B-cell childhood acute lymphoblastic leukemiaDormant

BBB

Indicative · Phase 3

76 / 100

hematopoietic and lymphoid system neoplasmActive

BBB

Indicative · Phase 4

76 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.